Insulin-like growth factor 1 and insulin-like growth factor binding protein 2 serum levels as potential biomarkers in differential diagnosis between chronic pancreatitis and pancreatic adenocarcinoma 
in reference to pancreatic diabetes

Barbara Włodarczyk; Anna Borkowska; Przemysław Włodarczyk; Ewa Małecka-Panas; Anita Gąsiorowska

doi:10.5114/pg.2020.95091

Abstract

1/2021 vol. 16

Original paper

Insulin-like growth factor 1 and insulin-like growth factor binding protein 2 serum levels as potential biomarkers in differential diagnosis between chronic pancreatitis and pancreatic adenocarcinoma in reference to pancreatic diabetes

Barbara Włodarczyk ¹

,

Anna Borkowska ²

,

Przemysław Włodarczyk ³

,

Ewa Małecka-Panas ¹

,

Anita Gąsiorowska ⁴

Department of Digestive Tract Diseases, Medical University of Lodz, Lodz, Poland
Department of Internal Medicine and Diabetology, Medical University of Lodz, Lodz, Poland
Faculty of Economics and Sociology, University of Lodz, Lodz, Poland
Clinic of Gastroenterology, Medical University of Lodz, Lodz, Poland

Gastroenterology Rev 2021; 16 (1): 36–42

DOI: https://doi.org/10.5114/pg.2020.95091

Online publish date: 2020/05/09

View full text

AMA

Włodarczyk B, Borkowska A, Włodarczyk P, Małecka-Panas E, Gąsiorowska A. Insulin-like growth factor 1 and insulin-like growth factor binding protein 2 serum levels as potential biomarkers in differential diagnosis between chronic pancreatitis and pancreatic adenocarcinoma in reference to pancreatic diabetes. Gastroenterology Review/Przegląd Gastroenterologiczny. 2021;16(1):36-42. doi:10.5114/pg.2020.95091.

APA

Włodarczyk, B., Borkowska, A., Włodarczyk, P., Małecka-Panas, E., & Gąsiorowska, A. (2021). Insulin-like growth factor 1 and insulin-like growth factor binding protein 2 serum levels as potential biomarkers in differential diagnosis between chronic pancreatitis and pancreatic adenocarcinoma in reference to pancreatic diabetes. Gastroenterology Review/Przegląd Gastroenterologiczny, 16(1), 36-42. https://doi.org/10.5114/pg.2020.95091

Chicago

Włodarczyk, Barbara, Anna Borkowska, Przemysław Włodarczyk, Ewa Małecka-Panas, and Anita Gąsiorowska. 2021. "Insulin-like growth factor 1 and insulin-like growth factor binding protein 2 serum levels as potential biomarkers in differential diagnosis between chronic pancreatitis and pancreatic adenocarcinoma in reference to pancreatic diabetes". Gastroenterology Review/Przegląd Gastroenterologiczny 16 (1): 36-42. doi:10.5114/pg.2020.95091.

Harvard

Włodarczyk, B., Borkowska, A., Włodarczyk, P., Małecka-Panas, E., and Gąsiorowska, A. (2021). Insulin-like growth factor 1 and insulin-like growth factor binding protein 2 serum levels as potential biomarkers in differential diagnosis between chronic pancreatitis and pancreatic adenocarcinoma in reference to pancreatic diabetes. Gastroenterology Review/Przegląd Gastroenterologiczny, 16(1), pp.36-42. https://doi.org/10.5114/pg.2020.95091

MLA

Włodarczyk, Barbara et al. "Insulin-like growth factor 1 and insulin-like growth factor binding protein 2 serum levels as potential biomarkers in differential diagnosis between chronic pancreatitis and pancreatic adenocarcinoma in reference to pancreatic diabetes." Gastroenterology Review/Przegląd Gastroenterologiczny, vol. 16, no. 1, 2021, pp. 36-42. doi:10.5114/pg.2020.95091.

Vancouver

Włodarczyk B, Borkowska A, Włodarczyk P, Małecka-Panas E, Gąsiorowska A. Insulin-like growth factor 1 and insulin-like growth factor binding protein 2 serum levels as potential biomarkers in differential diagnosis between chronic pancreatitis and pancreatic adenocarcinoma in reference to pancreatic diabetes. Gastroenterology Review/Przegląd Gastroenterologiczny. 2021;16(1):36-42. doi:10.5114/pg.2020.95091.

Introduction

Insulin-like growth factor 1 (IGF-1) has been connected with development of pancreatic ductal adenocarcinoma (PDAC).

Aim

To evaluate the serum concentration levels of IGF-1 and insulin-like growth factor binding protein 2 (IGFBP-2) in patients with chronic pancreatitis (CP) and PDAC. Their values in diabetes mellitus (DM) were also assessed.

Material and methods

The study included 83 patients with CP, 92 patients with PDAC, and 20 subjects as a control group. The concentrations of IGF-1 and IGFBP-2 were estimated with ELISA (Corgenix UK Ltd, R&D Systems).

Results

The IGF-1 was higher in CP compared with PDAC (81.11 ±57.18 ng/ml vs. 53.18 ±36.05 ng/ml, p < 0.001), and both CP and PDAC were different from controls (81.11 ±57.18 ng/ml vs. 70.66 ±16.57 ng/ml, p < 0.001 and 53.18 ±36.05 ng/ml vs. 70.66 ±16.57 ng/ml, p < 0.001). CP without cysts have lower IGF-1 compared to those with CP and cysts (60.35 ±34.68 ng/ml vs. 93.55 ±64.78 ng/ml, p < 0.05). IGF-1 in CP without DM was higher compared to IGF-1 in PDAC without DM (91.13 ±65.48 ng/ml vs. 54.75 ±40.41 ng/ml, p < 0.001). In CP and DM the IGF-1 was elevated in comparison to PDAC and DM (62.20 ±32.38 ng/ml vs. 48.45 ±24.88 ng/ml, p < 0.05). IGFBP-2 was higher in CP compared to PDAC (512.42 ±299.77 ng/ml vs 301.59 ±190.36 ng/ml, p < 0.001). In CP and PDAC the IGFBP-2 level was elevated compared to the control group (512.42 ±299.77 ng/ml vs. 51.92 ±29.40 ng/ml, p < 0.001 and 301.59 ±190.36 ng/ml vs. 51.92 ±29.40 ng/ml, p < 0.001). IGFBP-2 in CP without DM was higher compared to PDAC without DM (559.39 ±281.43 vs. 296.53 ±196.93, p < 0.001).